Chai Discovery Raises $400M as AI Drug Discovery Booms
Chai Discovery’s $400m raise triples its value to $3.8bn in seven months. It is a testament to the fact that AI drug discovery has moved from promise to deployment.
(July 15, 2026 – 4:01 pm)
Image by: Chai Discovery
Chai Discovery’s Series C funding of $400m valued the startup at an impressive $3.8bn—nearly triple its previous valuation of $1.3bn just seven months prior. Index Ventures led the round, with support from Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, OpenAI, and Thrive Capital.
This rapid growth is a result of Chai’s innovative approach to drug discovery. Founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud—all with backgrounds at OpenAI, Meta’s FAIR lab, and Stripe—Chai uses generative AI to design new medicines rather than solely relying on the identification of existing molecules.
Chai’s Technology:
- Generative AI for Antibody Design: Unlike traditional drug discovery methods that screen vast libraries of existing molecules, Chai employs generative AI to create novel antibodies and proteins from scratch.
- Impressive Results: In 2025, Chai-2 achieved double-digit success rates in lab testing, representing a significant (hundredfold) improvement over older methods.
- Commercial Success: Chai’s models are already deployed at leading pharmaceutical companies like Eli Lilly, Pfizer, and Novartis, highlighting its practical applications.
A Crowded but Richly Funded Field:
While Chai stands out due to its paying customers among big drugmakers, several other AI startups are also making waves in this space:
- Isomorphic Labs: Raised $2.1bn in May and partners with Novartis.
- Xaira Therapeutics: Launched with $1bn.
- Recursion: Secured more than $1bn in funding.
- Anthropic: Acquired a small drug design startup for about $400m.
- ByteDance: Entering the AI drug discovery race.
- Stanford’s James Zou: Building his own AI-biology firm.
The Future and Challenges:
Analysts predict the AI drug discovery market will reach $13.7bn by 2033, with Chai’s rapid valuation growth suggesting investor optimism. However, the next hurdle lies in translating promising AI-generated molecules into viable drugs—a lengthy process involving lab work, clinical trials, and regulatory approval.